INVERSAGO-PHARMA
15.3.2022 13:07:06 CET | Business Wire | Press release
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced today the dosing of the first participant with metabolic syndrome in a Phase 1b clinical trial.
This 28-day trial will test the pharmacokinetics and safety profile of Inversago’s lead molecule, INV-202, on a targeted population with metabolic syndrome. Topline results from 40 subjects are expected in the second half of the calendar year.
“We are pleased that the clinical trials for INV-202, our first-in-class, peripheral CB1 inhibitor, are moving ahead swiftly,” said Dr. François Ravenelle, Chief Executive Officer of Inversago. “This pharmacokinetic and safety study will also measure a number of well accepted biomarkers of metabolic disorders. Together, these results are expected to act as a guide for the next phase of INV-202’s development.”
Inversago is planning to launch its first Phase 2 study in patients with Diabetic Nephropathy (DN) shortly after results are available. DN involves a chronic loss of kidney function in people with type-1 and type-2 diabetes who also often present obesity. This patient profile allows for the objective measurement of primary endpoints specific to DN and secondary endpoints relevant to metabolic diseases at large. The company believes that this choice of indication provides the optimal proof of concept to demonstrate the therapeutic breadth of opportunity available to INV-202 and the rest of the Inversago pipeline.
Peripheral CB1 inverse agonists, such as Inversago’s lead INV-202 molecule, have demonstrated efficacy in addressing multiple pathways involved in renal injury. Aside effects on albuminuria in pre-clinical models, CB1 inverse agonists have shown clinical improvements in lipids, weight loss and glucose. Each of these effects have separately demonstrated reno-protective characteristics.
About Inversago Pharma
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF). For more information, visit inversago.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005525/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1NCE and Netmore Combine Cellular and LoRaWAN Access to Deliver Global IoT Coverage11.3.2026 08:40:00 CET | Press release
The two largest global providers of massive IoT networks partner to provide a combined offering of LoRaWAN® and Cellular connectivity. 1NCE now integrates Netmore’s LoRaWAN into the 1NCE OS platform, allowing customers to use both services seamlessly through its software stack. The new network addresses 90% of the LPWAN market and offers an unparalleled ability to eliminate coverage blind spots around the globe. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, today opened access for its customers to the LoRaWAN® services of Netmore, the world’s leading low power wide area network operator for massive IoT. With growing demand for low power long range connectivity, the Netmore LoRaWAN Network Server (LNS) Plugin provides 1NCE customers access to cellular and LoRaWAN IoT coverage options through one platform. The launch of the Netmore Plugin marks the beginning of strategic collaboration to expand the combined offering of the two
1NCE and Netmore Combine Cellular and LoRaWAN Access to Deliver Global IoT Coverage11.3.2026 08:40:00 CET | Press release
The two largest global providers of massive IoT networks partner to provide a combined offering of LoRaWAN® and Cellular connectivity. 1NCE now integrates Netmore’s LoRaWAN into the 1NCE OS platform, allowing customers to use both services seamlessly through its software stack. The new network addresses 90% of the LPWAN market and offers an unparalleled ability to eliminate coverage blind spots around the globe 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, today opened access for its customers to the LoRaWAN® services of Netmore, the world’s leading low power wide area network operator for massive IoT. With growing demand for low power long range connectivity, the Netmore LoRaWAN Network Server (LNS) Plugin provides 1NCE customers access to cellular and LoRaWAN IoT coverage options through one platform. The launch of the Netmore Plugin marks the beginning of strategic collaboration to expand the combined offering of the two b
Codethink Opens Early Access to IEC 61508 Mapping for the Eclipse Trustable Software Framework11.3.2026 08:07:00 CET | Press release
Preview release invites industry collaboration on open source approach to functional safety assessment EMBEDDED WORLD--Codethink today opened early access to its mapping between the Eclipse Trustable Software Framework (TSF) and IEC 61508, the international standard governing the functional safety of electrical and electronic systems. The mapping establishes a transparent relationship between the engineering principles of the Trustable Software Framework and the objectives defined in IEC 61508. By making this work available as an early preview, Codethink is inviting organisations interested in applying open source approaches to functional safety to review and begin working with the mapping while the work continues to mature. IEC 61508 forms the foundation of many domain-specific safety standards, including ISO 26262 for automotive systems. The early access reflects Codethink’s long-standing commitment to open development of software engineering methods. “This preview release reflects o
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering11.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma. The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for futur
Thales Launches SkyDefender: The Integral Air and Missile Defence Dome With Artificial Intelligence11.3.2026 07:00:00 CET | Press release
SkyDefender is a multi-layer, multi-domain Integrated Air and Missile Defence system providing full protection against all types of air threats, on land, at sea and in space. SkyDefender integrates a network of advanced sensors and effectors with a versatile command and control (C2) system. With its open and modular architecture, it is fully compatible with existing air defence systems. Combining Thales’ expertise in cybersecurity and advanced artificial intelligence through cortAIx, Thales AI accelerator, SkyDefender enables operational superiority and proactive defence against cyberattacks and evolving threats. Thales is capable of delivering this critical protection globally from today. As air and missile threats are evolving faster than ever, from slow-moving drones to hypersonic missiles, attacks are becoming increasingly complex, saturating and unpredictable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310398606/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom